Imunon Balance Sheet Health
Financial Health criteria checks 6/6
Imunon has a total shareholder equity of $13.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $21.9M and $8.5M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$15.70m |
| Equity | US$13.39m |
| Total liabilities | US$8.53m |
| Total assets | US$21.92m |
Recent financial health updates
Is Celsion (NASDAQ:CLSN) Using Debt Sensibly?
Dec 07
Is Celsion (NASDAQ:CLSN) Using Too Much Debt?
Aug 18Recent updates
Celsion changes name to Imunon (IMNN)
Sep 19Celsion says additional data shows placcine vaccine works against COVID-19 in animal model
Sep 01Celsion Q2 2022 Earnings Preview
Aug 12Celsion adds Moderna chief commercial officer as CEO
Jul 19Is Celsion (NASDAQ:CLSN) Using Debt Sensibly?
Dec 07Is Celsion (NASDAQ:CLSN) Using Too Much Debt?
Aug 18What We Learned About Celsion's (NASDAQ:CLSN) CEO Compensation
Dec 01Celsion slips 4% on Q3 earnings miss
Nov 16Financial Position Analysis
Short Term Liabilities: IMNN's short term assets ($18.2M) exceed its short term liabilities ($7.4M).
Long Term Liabilities: IMNN's short term assets ($18.2M) exceed its long term liabilities ($1.1M).
Debt to Equity History and Analysis
Debt Level: IMNN is debt free.
Reducing Debt: IMNN has no debt compared to 5 years ago when its debt to equity ratio was 45.1%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMNN has sufficient cash runway for 10 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: IMNN is forecast to have sufficient cash runway for 8 months based on free cash flow estimates, but has since raised additional capital.